The program is specifically designed to remove critical barriers to proper nutrition while helping myasthenia patients improve their daily quality of life, treatment adherence, and overall health.

Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease that can cause muscle weakness, fatigue and problems ...

Shares of Kyverna Therapeutics (KYTX) rose on Monday after the company announced long-term follow-up data from a pivotal trial for its lead asset, miv-cel, in generalized myasthenia gravis, an ...

The treatment landscape of generalised myasthenia gravis, a prototypic antibody-mediated disorder of the neuromuscular junction, has considerably evolved in the past 8 years.1 The approval of targeted ...

Johnson & Johnson (NYSE:JNJ) has reported new data from its Phase 3 Vivacity-MG3 trial showing that its therapy IMAAVY ...

MG-ADL and QMG at 24 weeks, further increasing confidence in Phase 3 trial . Totality of efficacy and safety data re ...

Boston, MA, USA and Oxford, UK -- 12 February 2026, Vitaccess, a leader in generating science-driven real-world evidence, has entered into an exclusive partnership with the Myasthenia Gravis ...

Myasthenia gravis (MG) medications can improve symptoms and quality of life, even though MG is chronic and has no current cure. Pyridostigmine bromide (Mestinon), a cholinesterase inhibitor, is often ...

SE recently presented new clinical data at the 2026 American Academy of Neurology meeting, showing VYVGART’s efficacy in ocular myasthenia gravis, broader generalized MG subtypes, and chronic ...

Add Yahoo as a preferred source to see more of our stories on Google. On April 20, at the 2026 American Academy of Neurology ...

Through 120 weeks of follow-up, IMAAVY delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+ ...